Clicky

Vanda Pharmaceuticals Inc.(VNDA)

Description: Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Keywords: Biopharmaceutical Organic Compounds Chemical Compounds Oncology Chemotherapy Alcohol Clinical Development Schizophrenia Depression Sleep Disorders Central Nervous System Disorders Major Depressive Disorder Nausea Nervous System Disorders Depressive Disorder Insomnia Pyridines Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Sedatives Pruritus Treatment Of Schizophrenia Chemotherapy Induced Nausea Triazoles Fanapt Iloperidone Post Operative Nausea

Home Page: www.vandapharma.com

VNDA Technical Analysis

2200 Pennsylvania Avenue NW
Washington, DC 20037
United States
Phone: 202 734 3400


Officers

Name Title
Dr. Mihael H. Polymeropoulos M.D. Founder, Pres, CEO & Chairman of The Board
Mr. Kevin Patrick Moran Sr. VP, CFO & Treasurer
Mr. Timothy Williams Sr. VP, Gen. Counsel & Sec.
Mr. Joakim Wijkstrom Sr. VP & Chief Marketing Officer
Mr. Gunther Birznieks Sr. VP of Bus. Devel.
Mr. Scott L. Howell Chief People Officer
Ms. Elizabeth Van Every Head of Corp. Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 30.303
Trailing PE: 68.9091
Price-to-Book MRQ: 1.1534
Price-to-Sales TTM: 1.5315
IPO Date: 2006-04-12
Fiscal Year End: December
Full Time Employees: 278
Back to stocks